A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

(2021) Partha Basu et al.   LANCET ONCOLOGY

Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study

(2020) Ana M. Rodriguez et al.   CANCER

Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial

(2020) Aimée R Kreimer et al.   JNCI-Journal of the National Cancer Institute

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination

(2020) Tsetsegsaihan Batmunkh et al.   VACCINE

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

(2019) Mélanie Drolet et al.   LANCET

Effectiveness of 1, 2, AND 3 Human Papillomavirus Vaccine doses against HPV-16/18 positive High-grade Cervical Lesions

(2019) Michelle L Johnson Jones et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses

(2019) Lauri E Markowitz et al.   JOURNAL OF INFECTIOUS DISEASES

Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination

(2018) Dorothy A Machalek et al.   JOURNAL OF INFECTIOUS DISEASES

Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs

(2018) Lauri E. Markowitz et al.   VACCINE

Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions

(2018) Christian Dehlendorff et al.   VACCINE

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

(2017) Warner K Huh et al.   LANCET

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials

(2017) Matti Lehtinen et al.   BMJ Open

Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis

(2016) K Cuschieri et al.   BRITISH JOURNAL OF CANCER

Effect of human papillomavirus vaccination on cervical cancer screening in Alberta

(2016) Jong Kim et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience

(2016) Suzanne M. Garland et al.   CLINICAL INFECTIOUS DISEASES

Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females

(2016) Annika M. Hofstetter et al.   JAMA Pediatrics

Challenges in Prevention and Care Delivery for Women with Cervical Cancer in Sub-Saharan Africa

(2016) Thomas C. Randall et al.   Frontiers in Oncology

Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents

(2015) S. F. La Vincente et al.   BMC PUBLIC HEALTH

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls

(2015) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

(2014) K Kavanagh et al.   BRITISH JOURNAL OF CANCER

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

(2014) K G J Pollock et al.   BRITISH JOURNAL OF CANCER

HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program

(2014) Sepehr N. Tabrizi et al.   JOURNAL OF CLINICAL VIROLOGY

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

(2014) Sepehr N Tabrizi et al.   LANCET INFECTIOUS DISEASES

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda

(2014) D. Scott LaMontagne et al.   VACCINE

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia

(2014) E. Crowe et al.   BMJ-British Medical Journal

Systematic review of the incidence and prevalence of genital warts

(2013) Harshila Patel et al.   BMC INFECTIOUS DISEASES

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

(2013) Dorota M Gertig et al.   BMC Medicine

Cervical cancer incidence and mortality in Fiji 2003-2009

(2012) Rebecca Kuehn et al.   AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY